Research Summary

My research program is focused on imaging cancer using MRI and novel PET tracers. At UCSF, I have developed the gallium-68 DOTA-TOC imaging program for neuroendocrine tumor staging, and am the principle investigator on the FDA IND. I have also successfully brought Ga-68 PSMA imaging to UCSF and am currently drafting the IND submission to allow for the evaluation of the clinical use of this agent. I am interested in using somatostatin receptor and PSMA based PET agents in order to distinguish neuroendocrine prostate cancer from adenocarcinoma. Additionally, I believe that the combination of MR and PET parameters will aid in the staging of cancers. Most straightforward is a study we are carrying out in low risk prostatectomy patients where we are evaluating the use of PET/MRI using Ga-68 PSMA and MR imaging of the primary tumor. In the setting of patients with metastatic disease, PET/MRI will likely have an even more important role, as response to treatment will change uptake of non-FDG tracers in ways that are not immediately clear and intepretation will likely rely on changes in MR imaging parameters such as diffusion weighted imaging (DWI).

Research Funding

  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2022 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA229354
  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • 2001
    Summa Cum Laude, Duke University
  • 2001
    Phi Beta Kappa, Duke University
  • 2006
    Trainee Research Prize, Radiological Society of North America
  • 2007
    W. S. Moore Award, Nominee, International Society of Magnetic Resonance in Medicine
  • 2011
    Magnum Cum Laude Merit Award, International Society of Magnetic Resonance in Medicine
  • 2012
    Roentgen Resident/Fellow Research Award, Radiological Society of North America
  • 2012
    Alexander Margulis Society Excellence in Research Award, UCSF
  • 2014
    Wylie J. Dodds Research Award, Society of Abdominal Radiology

Selected Publications

  1. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Sep 16.  View on PubMed
  2. Iravani A, Hope TA. RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials. J Nucl Med. 2021 Oct; 62(10):1438-1439.  View on PubMed
  3. Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, Sosa JA, Roman SA, Duh QY, Suh I. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery. 2021 Jul 31.  View on PubMed
  4. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2021 Jul 29.  View on PubMed
  5. Catana C, Laforest R, An H, Boada F, Cao T, Faul D, Jakoby B, Jansen FP, Kemp BJ, Kinahan PE, Larson PEZ, Levine MA, Maniawski P, Mawlawi O, McConathy J, McMillan A, Price JC, Rajagopal A, Sunderland J, Veit-Haibach P, Wangerin KA, Ying C, Hope TA. A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom. J Nucl Med. 2021 Jul 22.  View on PubMed
  6. Park S, Parihar AS, Bodei L, Hope TA, Mallak N, Millo C, Prasad K, Wilson D, Zukotynski K, Mittra E. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. J Nucl Med. 2021 Oct; 62(10):1323-1329.  View on PubMed
  7. Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery. 2021 Jul 20.  View on PubMed
  8. Marzella L, Czernin J, Hope T. Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope. J Nucl Med. 2021 Jul 01; 62(7):881-883.  View on PubMed
  9. de Kouchkovsky I, Aggarwal R, Hope TA. Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. Transl Androl Urol. 2021 Jul; 10(7):3130-3143.  View on PubMed
  10. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021 Jun 06.  View on PubMed
  11. Afaq A, Faul D, Chebrolu VV, Wan S, Hope TA, Haibach PV, Bomanji J. Pitfalls on PET/MRI. Semin Nucl Med. 2021 Sep; 51(5):529-539.  View on PubMed
  12. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721.  View on PubMed
  13. Koontz BF, Hope TA. More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer. JAMA Oncol. 2021 Apr 01; 7(4):563-564.  View on PubMed
  14. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021 04 01; 50(4):469-493.  View on PubMed
  15. Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 05; 299(2):248-260.  View on PubMed
  16. Bucknor MD, Hope TA. Reply: Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center. J Nucl Med. 2021 05 10; 62(5):748.  View on PubMed
  17. Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru AH, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2021 Jun 01; 27(11):2989-2995.  View on PubMed
  18. Hope TA, Graves CE, Calais J, Ehman E, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell J, Shen W, Roman S, Sosa JA, Kluijfhout W, Seib CS, Villanueva-Meyer J, Pampaloni MH, Suh I. Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study. J Nucl Med. 2021 Mar 05.  View on PubMed
  19. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021 05; 48(5):1626-1638.  View on PubMed
  20. Hope TA, Calais J. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021 02 27; 397(10276):768-769.  View on PubMed

Go to UCSF Profiles, powered by CTSI